
Imlunestrant vs Elacestrant: MOA and Clinical Trial Differences
While the newly approved imlunestrant (Inluriyo) and elacestrant (Orserdu) are both oral selective estrogen receptor degraders (SERDs) targeting ESR1 mutations indicated for adult patients with estrogen receptor (ER)–positive, HER2-negative advanced or …